BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 14581669)

  • 21. Huntington's disease - clinical signs, symptoms, presymptomatic diagnosis, and diagnosis.
    Shannon KM
    Handb Clin Neurol; 2011; 100():3-13. PubMed ID: 21496568
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Non-choreic movement disorders as initial manifestations of Huntington's disease.
    Becker N; Munhoz RP; Raskin S; Werneck LC; Teive HA
    Arq Neuropsiquiatr; 2007 Jun; 65(2B):402-5. PubMed ID: 17665004
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The neurology and natural history of patients with indeterminate CAG repeat length mutations of the Huntington disease gene.
    Panegyres PK; Goh JG
    J Neurol Sci; 2011 Feb; 301(1-2):14-20. PubMed ID: 21147489
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Phenotypic features of Huntington's disease-like 2.
    Walker RH; Jankovic J; O'Hearn E; Margolis RL
    Mov Disord; 2003 Dec; 18(12):1527-30. PubMed ID: 14673892
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The association of CAG repeat length with clinical progression in Huntington disease.
    Rosenblatt A; Liang KY; Zhou H; Abbott MH; Gourley LM; Margolis RL; Brandt J; Ross CA
    Neurology; 2006 Apr; 66(7):1016-20. PubMed ID: 16606912
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Huntington's disease: a clinical review.
    Roos RA
    Orphanet J Rare Dis; 2010 Dec; 5():40. PubMed ID: 21171977
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hereditary late-onset chorea without significant dementia: genetic evidence for substantial phenotypic variation in Huntington's disease.
    Britton JW; Uitti RJ; Ahlskog JE; Robinson RG; Kremer B; Hayden MR
    Neurology; 1995 Mar; 45(3 Pt 1):443-7. PubMed ID: 7898693
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical manifestations of homozygote allele carriers in Huntington disease.
    Cubo E; Martinez-Horta SI; Santalo FS; Descalls AM; Calvo S; Gil-Polo C; Muñoz I; Llano K; Mariscal N; Diaz D; Gutierrez A; Aguado L; Ramos-Arroyo MA;
    Neurology; 2019 Apr; 92(18):e2101-e2108. PubMed ID: 30867264
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The relationship between CAG repeat length and clinical progression in Huntington's disease.
    Ravina B; Romer M; Constantinescu R; Biglan K; Brocht A; Kieburtz K; Shoulson I; McDermott MP
    Mov Disord; 2008 Jul; 23(9):1223-7. PubMed ID: 18512767
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Functional decline in Huntington's disease.
    Feigin A; Kieburtz K; Bordwell K; Como P; Steinberg K; Sotack J; Zimmerman C; Hickey C; Orme C; Shoulson I
    Mov Disord; 1995 Mar; 10(2):211-4. PubMed ID: 7753064
    [TBL] [Abstract][Full Text] [Related]  

  • 31. What is the impact of education on Huntington's disease?
    López-Sendón JL; Royuela A; Trigo P; Orth M; Lange H; Reilmann R; Keylock J; Rickards H; Piacentini S; Squitieri F; Landwehrmeyer B; Witjes-Ane MN; Jurgens CK; Roos RA; Abraira V; de Yébenes JG;
    Mov Disord; 2011 Jul; 26(8):1489-95. PubMed ID: 21432905
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Objective assessment of motor slowness in Huntington's disease: clinical correlates and 2-year follow-up.
    van Vugt JP; Piet KK; Vink LJ; Siesling S; Zwinderman AH; Middelkoop HA; Roos RA
    Mov Disord; 2004 Mar; 19(3):285-97. PubMed ID: 15022182
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Novel BAC Mouse Model of Huntington's Disease with 225 CAG Repeats Exhibits an Early Widespread and Stable Degenerative Phenotype.
    Wegrzynowicz M; Bichell TJ; Soares BD; Loth MK; McGlothan JS; Mori S; Alikhan FS; Hua K; Coughlin JM; Holt HK; Jetter CS; Pomper MG; Osmand AP; Guilarte TR; Bowman AB
    J Huntingtons Dis; 2015; 4(1):17-36. PubMed ID: 26333255
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Huntington's disease with childhood and adolescent onset: course of disease, clinical presentation and diagnostic challenges].
    Thiels C; Stahl A; Saft C; Juckel G; Lücke T
    Fortschr Neurol Psychiatr; 2020 Oct; 88(10):661-667. PubMed ID: 32369858
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical-Genetic Associations in the Prospective Huntington at Risk Observational Study (PHAROS): Implications for Clinical Trials.
    ; Biglan KM; Shoulson I; Kieburtz K; Oakes D; Kayson E; Shinaman MA; Zhao H; Romer M; Young A; Hersch S; Penney J; Marder K; Paulsen J; Quaid K; Siemers E; Tanner C; Mallonee W; Suter G; Dubinsky R; Gray C; Nance M; Bundlie S; Radtke D; Kostyk S; Baic C; Caress J; Walker F; Hunt V; O'Neill C; Chouinard S; Factor S; Greenamyre T; Wood-Siverio C; Corey-Bloom J; Song D; Peavy G; Moskowitz C; Wesson M; Samii A; Bird T; Lipe H; Blindauer K; Marshall F; Zimmerman C; Goldstein J; Rosas D; Novak P; Caviness J; Adler C; Duffy A; Wheelock V; Tempkin T; Richman D; Seeberger L; Albin R; Chou KL; Racette B; Perlmutter JS; Perlman S; Bordelon Y; Martin W; Wieler M; Leavitt B; Raymond L; Decolongon J; Clarke L; Jankovic J; Hunter C; Hauser RA; Sanchez-Ramos J; Furtado S; Suchowersky O; Klimek ML; Guttman M; Sethna R; Feigin A; Cox M; Shannon B; Percy A; Dure L; Harrison M; Johnson W; Higgins D; Molho E; Nickerson C; Evans S; Hobson D; Singer C; Galvez-Jimenez N; Shannon K; Comella C; Ross C; Saint-Hilaire MH; Testa C; Rosenblatt A; Hogarth P; Weiner W; Como P; Kumar R; Cotto C; Stout J; Brocht A; Watts A; Eberly S; Weaver C; Foroud T; Gusella J; MacDonald M; Myers R; Fahn S; Shults C
    JAMA Neurol; 2016 Jan; 73(1):102-10. PubMed ID: 26569098
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Altered frontostriatal coupling in pre-manifest Huntington's disease: effects of increasing cognitive load.
    Wolf RC; Sambataro F; Vasic N; Schönfeldt-Lecuona C; Ecker D; Landwehrmeyer B
    Eur J Neurol; 2008 Nov; 15(11):1180-90. PubMed ID: 18754766
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cognitive decline in Huntington's disease expansion gene carriers.
    Baake V; Reijntjes RHAM; Dumas EM; Thompson JC; ; Roos RAC
    Cortex; 2017 Oct; 95():51-62. PubMed ID: 28843844
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rate of functional decline in Huntington's disease. Huntington Study Group.
    Marder K; Zhao H; Myers RH; Cudkowicz M; Kayson E; Kieburtz K; Orme C; Paulsen J; Penney JB; Siemers E; Shoulson I
    Neurology; 2000 Jan; 54(2):452-8. PubMed ID: 10668713
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Analysis of trinucleotide repeat expansion as a new mechanism of mutation in Huntington's chorea: theoretical and applied aspects].
    Illarioshkin SN; Ivanova-Smolenskaia IA; Markova ED; Nikol'skaia NN; Chabrashvili TZ; Insarova NG
    Genetika; 1996 Jan; 32(1):103-9. PubMed ID: 8647411
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identification of an expanded CAG repeat in the Huntington's disease gene (IT15) in a family reported to have benign hereditary chorea.
    MacMillan JC; Morrison PJ; Nevin NC; Shaw DJ; Harper PS; Quarrell OW; Snell RG
    J Med Genet; 1993 Dec; 30(12):1012-3. PubMed ID: 8133497
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.